Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Observational cohort study to evaluate the safety of agomelatine in standard medical practice in depressed patients: a prospective, observational (non interventional), international, multicentre cohort study

Next Previous
Trial Profile

Observational cohort study to evaluate the safety of agomelatine in standard medical practice in depressed patients: a prospective, observational (non interventional), international, multicentre cohort study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Agomelatine (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions

Most Recent Events

  • 29 Jul 2020 Results (N=1484), of a 1-year multicenter observational study in France, published in the Clinical Drug Investigation
  • 20 Sep 2016 Interim results (n=625) presented at the 29th Annual Congress of the European College of Neuropsychopharmacology.
  • 01 Dec 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top